On April 15, 2022, Broadwood Capital, Inc. announced that it has been, and might continue to be, in contact with members of OncoCyte Corporation's management, the board of directors of the Company, other significant shareholders and others regarding alternatives that the Company could employ to maximize the creation of shareholder value over time.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.48 USD | +1.64% | -0.80% | -0.80% |
Apr. 25 | OncoCyte Corporation announced that it has received $15.8 million in funding | CI |
Apr. 16 | Broadwood Capital, Inc. Engages with OncoCyte Corporation | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.80% | 33.11M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- OCX Stock
- News OncoCyte Corporation
- Broadwood Capital Engages in Discussions with OncoCyte Corporation